Newsletter Subscription

Enter Name and Email

NeuroAct Communication - Newsletter - October 2011

 

Expertise in Neuropharmacology

  www.neuroact.com

 

    

 

   

Autumn News

9th International Meeting on Early Phases of Mental Disorders

Adrian Newman-Tancredi Ph.D. will be presenting at the above meeting in Santander (Spain) on 22 October 2011.
The full conference program is here.
If you are interested in this meeting or wish to know more about Adrian's neuropharmacology lectures, Contact.

 

ECNP Brainstorming Session

Adrian co-chaired a lively session at the 24th meeting of the ECNP (European College of Neuropsychopharmacology) on 6 Sept. 2011 in Paris, France. More information here.

 

Consulting assignments completed

NeuroAct Communication recently completed further consulting assignments. One involved giving expert comment on an antipsychotic drug in development phase to a biomedical market research organisation. Another assignment consisted of giving lectures on the mechanisms of action of antipsychotics to hospital-based psychiatrists.

For more information: Consulting services.

  

 

 

 

 

 

 

 

 

 

 

 

 

NeuroAct Communication is an independent consulting service founded by Adrian Newman-Tancredi Ph.D.,
an experienced pharmaceutical industry professional.

Find out more about Adrian in his Executive Profile

Note: Adrian is progressively transitioning to take up research management responsibilities at Neurolixis Inc., a CNS-focused drug discovery and early development start-up he has co-founded with other experienced neuroscience researchers. 

 

 

NeuroAct Communication advises lifescience companies and funding agencies on neuropharmacology and central nervous system drug discovery programs.  

 

 

Scientific Communication

 

Just Published:

Anatomically Selective Serotonergic Type 1A and Serotonergic Type 2A Therapies for Parkinson's Disease: An Approach to Reducing Dyskinesia without Exacerbating Parkinsonism?

Huot P, Fox SH, Newman-Tancredi A, Brotchie JM.
J Pharmacol Exp Ther. 2011 Oct;339(1):2-8. 

Evaluation of milnacipran, in comparison with amitriptyline, on cold and mechanical allodynia in a rat model of neuropathic pain.

Berrocoso E, Mico JA, Vitton O, Ladure P, Newman-Tancredi A, Depoortère R, Bardin L.
Eur J Pharmacol. 2011 Mar 25; 655(1-3):46-51.

Effects of milnacipran, duloxetine and indomethacin, in polyarthritic rats using the Randall-Selitto model.

Mico JA, Berrocoso E, Vitton O, Ladure P, Newman-Tancredi A, Bardin L, Depoortère R.
Behav Pharmacol. 2011 Sep; 22(5&6):599-606.

To find out more about Adrian's scientific communication, see his Publications.